Lannett (LCI) – Lawsuits Will Wipe Out The Equity" Citron ResearchGuest Post
If Even Modest Price Cuts Hit Either of Lannett’s Cash Cow Drugs, It Will Violate Its Debt Covenants
$13-$15 Near Term Target
Equity Worthless Over Long-Term
Over the past year, almost every media outlet in the US has dissected the pharmaceutical industry to expose the culprits of rampant opportunistically driven price gouging. We are . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.